Functional attributes of antibodies, effector cells, and target cells affecting nk cell-mediated antibody-dependent cellular cytotoxicity

A. Robin Temming, Steven W. de Taeye, Erik L. de Graaf, Louise A. de Neef, Gillian Dekkers, Christine W. Bruggeman, Jana Koers, Peter Ligthart, Sietse Q. Nagelkerke, James C. Zimring, Taco W. Kuijpers, Manfred Wuhrer, Theo Rispens, Gestur Vidarsson

Research output: Contribution to journalArticleAcademicpeer-review

49 Citations (Scopus)

Abstract

Ab-dependent cellular cytotoxicity (ADCC) is one of the most important effector mechanisms of tumor-targeting Abs in current immunotherapies. In ADCC and other Ab-dependent activation of myeloid effector cells, close cell-cell contact (between effector and target cell) and formation of immunological synapses are required. However, we still lack basic knowledge on the principal factors influencing ADCC potential by therapeutic Abs. In this study we investigated the combined roles of five factors affecting human NK cell-mediated ADCC, namely: 1) Ag density, 2) target cell membrane composition, 3) IgG FcgR polymorphism, 4) FcgR-blocking cytophilic Abs, and 5) Ab fucosylation.We demonstrate that the magnitude of NK cell-mediated ADCC responses is predominantly influenced by Ag density and Ab fucosylation. Afucosylation consistently induced efficient ADCC, even at very low Ag density, where fucosylated target Abs did not elicit ADCC. On the side of the effector cell, the FcgRIIIa-Val/Phe158 polymorphism influenced ADCC potency, with NK cells expressing the Val158 variant showing more potent ADCC. In addition, we identified the sialic acid content of the target cell membrane as an important inhibitory factor for ADCC. Furthermore, we found that the presence and glycosylation status of aspecific endogenous Abs bound to NK cell FcgRIIIa (cytophilic Abs) determine the blocking effect on ADCC. These five parameters affect the potency of Abs in vitro and should be further tested as predictors of in vivo capacity.
Original languageEnglish
Pages (from-to)3126-3135
JournalJournal of immunology (Baltimore, Md.
Volume203
Issue number12
DOIs
Publication statusPublished - 2019

Cite this